Literature DB >> 16061981

A new automated fourth-generation HIV screening assay with sensitive antigen detection module and high specificity.

Bernard Weber.   

Abstract

New screening enzyme immunoassays, which permit the simultaneous detection of HIV antigens reduce the diagnostic window period between the time of immunodeficiency virus (HIV) infection and seroconversion. The VIDAS HIV DUO Ultra is an enzyme-linked fluorescent assay (ELFA) for the screening of HIV infection. It is performed with the fully automated VIDAS or mini-VIDAS instruments, which are so-called walk away systems. The detection limit is 3 pg of HIV-1 p24 Ag/mL serum. HIV antibody is detected with the same sensitivity as stand-alone third-generation antibody tests. The total incubation time is about 2 h. Results are calculated, interpreted, and printed by the VIDAS instrument. Usually, fourth-generation assays demand a special algorithm for the analysis of reactive samples. For the anti-HIV part of the assay, confirmation of reactivity should be done with an assay that lacks the p24-antigen detection module and when reactivity persists subsequently by immunoblot. For the p24-antigen part, confirmation of reactivity should be analyzed in an assay that lacks the anti-HIV detection part.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061981     DOI: 10.1385/1-59259-907-9:245

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting.

Authors:  Mark W Pandori; John Hackett; Brian Louie; Ana Vallari; Teri Dowling; Sally Liska; Jeffrey D Klausner
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

2.  Acute HIV-1 infection is as common as malaria in young febrile adults seeking care in coastal Kenya.

Authors:  Eduard J Sanders; Peter Mugo; Henrieke A B Prins; Elizabeth Wahome; Alexander N Thiong'o; Grace Mwashigadi; Elisabeth M van der Elst; Anisa Omar; Adrian D Smith; Susan M Graham
Journal:  AIDS       Date:  2014-06-01       Impact factor: 4.177

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.